The median OS achieved with targeted monotherapy in IDH1- and IDH2-mutant untreated AML—12.6 months and 11.3 months, respectively—is favorable compared to that of azacitidine (10.3 months) and decitabine (7.7 months) in a similar patient population [24,25,26,27]. Here, IDH2 is linked to acute myeloid leukemia.